Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KLRF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KLRF1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled (<1 EU/μg). Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View KLRF1 Products |
| Gene Delivery | KLRF1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for flow cytometry and functional assays. |
View KLRF1 Products |
| Benchmark Ab | Anti-KLRF1 Recombinant Antibody Recombinant positive control derived from benchmark clinical clones. Sequence Verified. |
View KLRF1 Products |
| Validator | KLRF1 siRNA Set For knockdown verification in primary NK cells or cell lines. |
View KLRF1 Products |
| Related Target A | CLEC2B (AICL) The physiological ligand for KLRF1. Crucial for validating receptor-ligand blocking or activation. |
View CLEC2B Products |
| Related Target B | NCR3 (NKp30) Synergistic NK-cell activating receptor. Essential for multi-specific NK-cell engager screening panels. |
View NCR3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Cynomolgus, and Mouse KLRF1 ortholog proteins available with >95% purity and verified Theoretical MW |
| Homodimerization validation | HEK293-expressed ECD-Fc fusion proteins preserving native dimeric conformation and glycosylation patterns |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization |
| False Positives | Validated siRNA included for specificity and target knockdown verification |
Live KLRF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KLRF1 (NKp80) therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific NK cell engagers (NKCEs) and CAR-NK cell therapies. As first-generation immunotherapies reach the clinic, the next wave of R&D is targeting the precise modulation of NK cell activation pathways while mitigating off-target myeloid cell activation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| NK Cell Engager (Bispecific/Trispecific) | Innate Pharma, Sanofi | Acute Myeloid Leukemia (AML), Solid Tumors | Affinity & Binding Kinetics (Requires high-purity KLRF1 ECD-Fc and CLEC2B proteins) |
| Monoclonal Antibody (mAbs) | Academic Institutions, Biotech Startups | Autoimmune Diseases, Inflammatory Disorders | Blocking & Activation Assays (Requires Lentivirus for Stable Cell Line development) |
| CAR-NK / CAR-T Cell Therapy | Clinical-stage Cell Therapy Companies | Hematological Malignancies | Target Expression & Specificity Validation (Requires Sequence Verified KLRF1 siRNA & ORF) |